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Biomade Technology Foundation, Groningen,
etherlands
anoparticles are being applied in diverse ways in
edicine In virtually all applications they are so con-
tructed as to selectively associate with a specific cell
ype or cell surface ligand or small molecule or protein
r oligonucleotide. From that point their characteristics
iverge depending on their function. Analytical (ex vivo)
iagnostics employ gold and silver and semiconductor
uantum dots. Their properties are optimized for multi-
lexing at very high levels of selectivity and sensitivity
own to attomolar concentrations. In vivo applications
ouple the selective recognition aspect of a diagnostic
ool to the imaging and/or the therapeutic power to the
anoparticle. That therapeutic power can be to deliver a
rug or to be itself the therapeutic agent by delivering
lethal dose of radiation or interacting with externally
pplied focussed ultrasound or magnetic fields to heat the
mmediate surroundings and induce hyperthermic cell
eath.




arameters of nanoparticles determining
istribution and accumulation in secondary target
rgans
olfgang Kreyling
GSF—National Research Center for Environment and
ealth, GSF-Focus Network: Aerosols and Health and
nstitute for Inhalation Biology, Neuherberg/Munich,
ermany
anoparticles are increasingly used in a wide range of
pplications in science, technology and medicine. Since
hey are produced for specific purposes which cannot be
et by larger particles and bulk material they are likely to
e highly reactive, in particular, with biological systems.
There is clear evidence that nanoparticles can cross
ody membranes and reach and accumulate in secondary
arget organs like heart, liver, spleen, brain and reproduc-
ive organs and foetus eventually causing adverse effects
n cardiac function and blood coagulation.
To quantitatively determine accumulated fractions in
uch organs the ultimate aim is to quantitatively bal-172S (2007) S1–S240 S35
ance the fractions of nanoparticles in all interesting
organs and tissues of the body including the remainder
body and total excretion collected between applica-
tion and autopsy. Substantial uncertainty will remain
if only selected organs are analyzed. Since these gross
determinations of nanoparticle contents in organs and
tissues do not provide microscopic information on the
anatomical and cellular location of nanoparticles such
studies are recommended to be complemented by elec-
tron microscopy analysis.
In addition, the role of particle parameters determin-
ing this translocation dynamics remains to be not fully
understood. Nanoparticle parameters such as size, sur-
face charge, and surface ligands. The current knowledge
on systemic translocation of ultrafine particles in man
and animal models and an estimate of accumulating
particle number, surface area and mass in secondary tar-
get organs during short-term and chronic exposure will
be discussed in order to demonstrate the relevance of
translocated fractions of nanoparticles.
doi:10.1016/j.toxlet.2007.05.121
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Nanomaterials: Ensuring their safety
Philippe Martin
Eur. Commission, Brussels, Belgium
Nanotechnologies should find applications in almost any
imaginable domain because of their expected benefits.
Yet, some exhibit potential risks. In the event, products
of nanotechnologies now have entered the market by the
hundreds. Their further development and market uptake
depend on citizens’ safety, trust, and acceptance. The
European Union gave itself an Action Plan to ensure the
“safe, integrated, and responsible development of nan-
otechnologies”. The presentation will review progress
made on the European Action Plan and, in particular, pro-
vide an update on the work of the independent Scientific
Committees, which, through their Scientific Opinion,
play a key role in informing Community policy making.
doi:10.1016/j.toxlet.2007.05.122
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Carbon nanotubes and their inﬂuence on cell
viability and function
